Local or systemic treatment for New World cutaneous leishmaniasis? Re-evaluating the evidence for the risk of mucosal leishmaniasis.
Johannes Blum, Diana N J Lockwood, Leo Visser...
https://pubmed.ncbi.nlm.nih.gov/24029394/Actively Recruiting
Led by Universidad de Antioquia · Updated on 2026-04-02
96
Participants Needed
1
Research Sites
8 weeks
Total Duration
Researchers are evaluating the safety and effectiveness of arnica tincture as a topical treatment for localized cutaneous leishmaniasis CL, a parasitic skin disease caused by Leishmania species. The study compares arnica tincture to the current local treatment with intralesional pentavalent antimonials. This trial builds on prior research showing positive results for arnica tincture in Colombia and aims to offer a potentially safer option with fewer systemic side effects. This is a randomized, single-blind clinical trial including two treatment groups. One group will apply arnica tincture topically three times a day for 30 days, while the other will receive intralesional injections of pentavalent antimonials once weekly for five weeks, dosed by lesion size. Both treatments target localized skin lesions caused by CL, and the study evaluates the safety and healing outcomes of these approaches. Participants will be assessed through clinical examinations of their lesions at regular intervals up to 90 days post-treatment to measure healing rates. Safety will be monitored by recording adverse effects. Follow-up visits will continue for more than three months to observe final healing status and any treatment-related issues. The trial aims to provide data on both effectiveness and side effects to inform future treatment choices for CL patients.
CONDITIONS
Arnica Tincture Fot the Treatment of Cutaneous Leishmaniasis II.
I
Iván D Velez, PhD
L
Liliana Lopez, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Universidad de Antioquia
Lead Sponsor
INNOVATION CORPORATION FOR THE DEVELOPMENT OF PRODUCTS FOR TROPICAL DISEASES (CIDEPRO)
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 30 days for arnica tincture or 5 weeks for pentavalent antimonials
Participants apply arnica tincture topically three times a day on all lesions for 30 days, or receive intralesional pentavalent antimonials once a week for 5 weeks.
Weekly visits for up to 5 weeks for those receiving pentavalent antimonials; participants using arnica tincture apply it at home three times daily
Duration - Up to 75 days post-treatment
Participants are monitored for healing and safety outcomes after treatment ends, including assessment of lesion healing at day 90 and day 105 post-treatment.
Approximately 2 follow-up visits after treatment completion
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Johannes Blum, Diana N J Lockwood, Leo Visser...
https://pubmed.ncbi.nlm.nih.gov/24029394/Olga Laura Sena Almeida, Jussamara Brito Santos
https://pubmed.ncbi.nlm.nih.gov/21738967/O Velasco-Castrejon, B C Walton, B Rivas-Sanchez...
https://pubmed.ncbi.nlm.nih.gov/9311641/Steffen Wagner, Andreas Suter, Irmgard Merfort
https://pubmed.ncbi.nlm.nih.gov/15490315/Tatiana S Tiuman, Adriana O Santos, Tânia Ueda-Nakamura...
https://pubmed.ncbi.nlm.nih.gov/21605997/Franziska M Jürgens, Fabian C Herrmann, Sara M Robledo...
https://pubmed.ncbi.nlm.nih.gov/35456576/Tommaso Iannitti, Julio César Morales-Medina, Paolo Bellavite...
https://pubmed.ncbi.nlm.nih.gov/25171757/B L Herwaldt
https://pubmed.ncbi.nlm.nih.gov/10513726/Ludovic Reveiz, Ana Nilce Silveira Maia-Elkhoury, Rubén Santiago Nicholls...
https://pubmed.ncbi.nlm.nih.gov/23637917/Iván Vélez, Liliana López, Ximena Sánchez...
https://pubmed.ncbi.nlm.nih.gov/20682881/Universidad de Antioquia
Lead Sponsor
INNOVATION CORPORATION FOR THE DEVELOPMENT OF PRODUCTS FOR TROPICAL DISEASES (CIDEPRO)
Collaborating Sponsor